JP7563975B2 - 治療のための薬剤、使用及び方法 - Google Patents

治療のための薬剤、使用及び方法 Download PDF

Info

Publication number
JP7563975B2
JP7563975B2 JP2020502415A JP2020502415A JP7563975B2 JP 7563975 B2 JP7563975 B2 JP 7563975B2 JP 2020502415 A JP2020502415 A JP 2020502415A JP 2020502415 A JP2020502415 A JP 2020502415A JP 7563975 B2 JP7563975 B2 JP 7563975B2
Authority
JP
Japan
Prior art keywords
antibody
seq
chain variable
variable region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527152A (ja
JP2020527152A5 (https=
Inventor
ロン，ラーズ，クリスチャン ビルマン
マリク，イブラヒム，ジョン
スタヴェンハーゲン，ジェフリー，ビー
クリステンセン，セーレン
エゲブジャーグ，ジャン
スツマン，ティナ
ジェリッツェン，アーノウト
デン ブリンク，エドワード ヴァン
パレン，ポール
トラブジャーグ，エスベン
ダイアバーグ ランド，カスパー
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2020527152A publication Critical patent/JP2020527152A/ja
Publication of JP2020527152A5 publication Critical patent/JP2020527152A5/ja
Priority to JP2024085982A priority Critical patent/JP2024119866A/ja
Application granted granted Critical
Publication of JP7563975B2 publication Critical patent/JP7563975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020502415A 2017-07-20 2018-07-18 治療のための薬剤、使用及び方法 Active JP7563975B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024085982A JP2024119866A (ja) 2017-07-20 2024-05-28 治療のための薬剤、使用及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20
DKPA201700419 2017-07-20
PCT/EP2018/069460 WO2019016247A2 (en) 2017-07-20 2018-07-18 AGENTS, USES AND METHODS OF TREATMENT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024085982A Division JP2024119866A (ja) 2017-07-20 2024-05-28 治療のための薬剤、使用及び方法

Publications (3)

Publication Number Publication Date
JP2020527152A JP2020527152A (ja) 2020-09-03
JP2020527152A5 JP2020527152A5 (https=) 2021-07-29
JP7563975B2 true JP7563975B2 (ja) 2024-10-08

Family

ID=63113476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502415A Active JP7563975B2 (ja) 2017-07-20 2018-07-18 治療のための薬剤、使用及び方法
JP2024085982A Withdrawn JP2024119866A (ja) 2017-07-20 2024-05-28 治療のための薬剤、使用及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024085982A Withdrawn JP2024119866A (ja) 2017-07-20 2024-05-28 治療のための薬剤、使用及び方法

Country Status (25)

Country Link
US (2) US10894833B2 (https=)
EP (1) EP3655438A2 (https=)
JP (2) JP7563975B2 (https=)
KR (1) KR102800556B1 (https=)
CN (3) CN110945029B (https=)
AR (1) AR112563A1 (https=)
AU (1) AU2018303175B2 (https=)
BR (1) BR112019005428A2 (https=)
CA (1) CA3069391A1 (https=)
CL (1) CL2020000070A1 (https=)
CO (1) CO2019014090A2 (https=)
CR (1) CR20200027A (https=)
DO (1) DOP2020000006A (https=)
EA (1) EA201992688A1 (https=)
EC (1) ECSP20002935A (https=)
IL (1) IL271728B2 (https=)
JO (1) JOP20200007A1 (https=)
MA (1) MA49633A (https=)
NI (1) NI202000005A (https=)
PE (1) PE20210467A1 (https=)
PH (1) PH12019502869A1 (https=)
RU (1) RU2019140933A (https=)
SG (1) SG11201912228WA (https=)
TW (1) TW201908342A (https=)
WO (1) WO2019016247A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
US20200392229A1 (en) * 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
CA3183994A1 (en) * 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2017009327A1 (en) 2015-07-13 2017-01-19 H. Lundbeck A/S Antibodies that bind to sortilin and inhibit the binding of progranulin

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2003287930A1 (en) 2002-12-20 2004-07-14 Neuronicon Aps Modulation of activity of neurotrophins
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
EP3225251B1 (en) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2009132656A2 (en) 2008-04-27 2009-11-05 H. Lundbeck A/S Design of specific ligands to sortilin
EP2293667A4 (en) * 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
US10149836B2 (en) * 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
IL295414B2 (en) * 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EA201992350A1 (ru) * 2017-04-05 2020-03-23 Симфоген А/С Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
TWI809147B (zh) * 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2017009327A1 (en) 2015-07-13 2017-01-19 H. Lundbeck A/S Antibodies that bind to sortilin and inhibit the binding of progranulin

Also Published As

Publication number Publication date
EP3655438A2 (en) 2020-05-27
AU2018303175B2 (en) 2025-01-23
CN119161481A (zh) 2024-12-20
CA3069391A1 (en) 2019-01-24
CN110945029B (zh) 2024-10-01
JP2020527152A (ja) 2020-09-03
TW201908342A (zh) 2019-03-01
AR112563A1 (es) 2019-11-13
CR20200027A (es) 2020-04-17
NI202000005A (es) 2020-05-20
WO2019016247A3 (en) 2019-06-20
ECSP20002935A (es) 2020-02-28
US20210292414A1 (en) 2021-09-23
DOP2020000006A (es) 2020-07-15
MA49633A (fr) 2020-05-27
KR102800556B1 (ko) 2025-04-24
BR112019005428A2 (pt) 2019-07-16
AU2018303175A1 (en) 2020-01-16
CN110945029A (zh) 2020-03-31
KR20200031610A (ko) 2020-03-24
PH12019502869A1 (en) 2020-09-28
EA201992688A1 (ru) 2020-05-20
IL271728A (en) 2020-02-27
US20190023788A1 (en) 2019-01-24
CL2020000070A1 (es) 2020-06-12
SG11201912228WA (en) 2020-01-30
US10894833B2 (en) 2021-01-19
PE20210467A1 (es) 2021-03-08
JP2024119866A (ja) 2024-09-03
WO2019016247A2 (en) 2019-01-24
CN119161480A (zh) 2024-12-20
RU2019140933A (ru) 2021-08-20
CO2019014090A2 (es) 2020-01-17
RU2019140933A3 (https=) 2021-10-28
IL271728B1 (en) 2024-01-01
JOP20200007A1 (ar) 2020-01-15
IL271728B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
US12331123B2 (en) Agent, uses and methods for treatment
JP7563975B2 (ja) 治療のための薬剤、使用及び方法
HK1254356B (en) Antibodies that bind to sortilin and inhibit the binding of progranulin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240926

R150 Certificate of patent or registration of utility model

Ref document number: 7563975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150